Table 4. Subgroup Analyses.
| Variable | Patients, No. | Incidence rate (95% CI) per 1000 person-years | HR (95% CI) |
|---|---|---|---|
| Age | |||
| ≥60 y | |||
| SGLT2 inhibitor | 5529 | 11.4 (10.1-12.8) | 0.83 (0.70-0.98) |
| GLP-1 RA | 493 | 13.6 (12.2-15.2) | 1 [Reference] |
| <60 y | |||
| SGLT2 inhibitor | 4538 | 6.3 (5.3-7.5) | 0.88 (0.69-1.12) |
| GLP-1 RA | 556 | 7.2 (6.1-8.6) | 1 [Reference] |
| Sex | |||
| Male | |||
| SGLT2 inhibitor | 5855 | 6.7 (5.8-7.8) | 0.62 (0.51-0.75) |
| GLP-1 RA | 514 | 11.1 (9.8-12.5) | 1 [Reference] |
| Female | |||
| SGLT2 inhibitor | 4394 | 11.8 (10.3-13.4) | 0.93 (0.77-1.11) |
| GLP-1 RA | 565 | 12.4 (10.9-14.1) | 1 [Reference] |
| HbA1c level | |||
| ≥7% | |||
| SGLT2 inhibitor | 9222 | 9.0 (8.1-9.9) | 0.83 (0.72-0.96) |
| GLP-1 RA | 1029 | 10.8 (9.8-11.9) | 1 [Reference] |
| <7% | |||
| SGLT2 inhibitor | 824 | 9.5 (6.7-13.5) | 0.85 (0.51-1.43) |
| GLP-1 RA | 37 | 11.2 (7.7-16.2) | 1 [Reference] |
| eGFR level | |||
| ≥90 mL/min/1.73 m2 | |||
| SGLT2 inhibitor | 4878 | 7.3 (6.2-8.5) | 0.62 (0.51-0.77) |
| GLP-1 RA | 481 | 11.7 (10.3-13.4) | 1 [Reference] |
| <90 mL/min/1.73 m2 | |||
| SGLT2 inhibitor | 5206 | 10.9 (9.7-12.4) | 0.95 (0.80-1.14) |
| GLP-1 RA | 550 | 11.5 (10.1-13.1) | 1 [Reference] |
| UACR level | |||
| ≥30 mg/g | |||
| SGLT2 inhibitor | 4721 | 9.0 (7.8-10.4) | 0.97 (0.79-1.20) |
| GLP-1 RA | 673 | 9.2 (7.9-10.6) | 1 [Reference] |
| <30 mg/g | |||
| SGLT2 inhibitor | 5315 | 8.7 (7.6-10.1) | 0.65 (0.54-0.78) |
| GLP-1 RA | 408 | 13.5 (12.0-15.2) | 1 [Reference] |
Abbreviations: eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagonlike peptide-1 receptor agonist; HbA1c, hemoglobin A1c; HR, hazard ratio; SGLT2, sodium-glucose cotransporter 2; UACR, urine albumin-to-creatinine ratio.